Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Klotho Neuroscience, Inc. Announces an Approach to Increase Longevity and Healthy Life Span - Replace a Silenced Gene Called ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

You’ve probably familiar with the abs muscles—the ones you see poppin' on sculpted celebs like J.Lo or Halle Berry, but there’s way more to core strength than those visible six-pack muscles.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.